Background: Colorectal cancer (CRC) is the third most common cause of cancer-related death in the US. One out of four patients presenting with conventionally staged node negative disease (AJCC Stage I and II), and over 50% of patients with Stage III disease will develop local recurrence and/ or metastases. Across all stages, approximately 30% of patients will develop distant metastases. Once metastases become clinically evident prognosis is often fatal. Biomarkers capable of predicting progression, risk stratification and therapeutic benefit are needed. CRCSC markers will identify a group of patients at high risk for progression. ALDH1 has been reported as a cancer stem cell marker in pancreatic, breast, prostate, and lung cancer, multiple myeloma and leukemia. By IHC analysis, human ALDH1B1 was found to be expressed at high levels in the small intestine, liver, and pancreas, and at lower levels in the lung and colon. This study aims to investigate ALDH1B1 expression in different types of colorectal carcinoma and correlate this expression with different clinicopathological parameters.
Introduction
Colorectal cancer (CRC) is the third most common cause of cancer-related death in the US. Across all stages, approximately 30% of patients will develop distant metastases (Siegel et al., 2011). Biomarkers capable of predicting progression, risk stratification and therapeutic benefit are needed. Cancer stem cells are thought to be responsible for tumor initiation, dissemination and treatment failure. Therefore, CRC stem cell (CRCSC) markers will identify a group of patients at high risk for progression (Manfredi et al., 2006). ALDH1A1 and ALDH1B1 belong to the family 1 of ALDH superfamily (Stagos et al., 2010 
Results
The age range of the patients included in this study was 29-80 years, with a mean ± SD and a median of 56.2 ± 13.5 and 57.5 years respectively. Males were 27/50 (54%) and females were 23/50 (46%). Regarding tumor size, 21/50 (16%) cases were ≤5 cm and 29/50 (84%) cases were > 5cm. 31/50 (62%) cases were left sided tumors whereas 19/50 (38%) cases were right sided. • Nineteen cases (19/50; 38%) were grade I; well differentiated tumor > 95% gland forming.
• Twenty five cases (25/50; 50%) were grade II; moderately differentiated tumor 50-95% gland forming.
• Six cases (6/50; 12%) were grade III; poorly differentiated tumor < 50% gland forming.
• Signet ring cell carcinoma were considered to be grade III ALDH1B1 protein expression appeared as brownish granular cytoplasmic staining. It showed variation in its expression among different types and grades of colorectal carcinoma. ALDH1B1 was strongly expressed in 12/50 (58%) of cases of colorectal carcinoma from them 8/12 (66.67%) cases were conventional adenocarcinoma. ALDH1B1 was moderately expressed in 31/50 (36%) of cases and weekly expressed in 7/50 (6%) of cases. Among the cases strongly expressing ALDH1B1 6/12 was grade II and 4/12 was grade III tumor. Among the studied parameters; ALDH1B1 showed significant correlation with tumor size (p= 0.021), tumor grade (p= 0.035), and lymph node status (p= 0.038) as shown in. However, statistical evaluation of ALDH1B1 expression according to age, sex, tumor location, histologic type, depth of tumor invasion and LVI showed no significance. 
Discussion
Our study included 50 specimens of colorectal carcinoma removed by colectomy. These tumors were investigated for the expression of ALDH1B1 glycoprotein. The IRS of ALDH1B1 was defined in tumor tissue and was correlated with some clinicopathological variables (age, sex, tumor size, tumor location, tumor grade, depth of tumor invasion, surgical resection margin, LVI and lymph node status). The age range of the studied patients was 29-80 years, with the highest age incidence was between 50-59 years, with mean ± SD was 56.2 ± 13.5 years, the median age was 57.5 years. The male to female ratio was 1.3: 1.
Immunohistochemical findings:
Current study showed that ALDH1B1 was expressed in all cases (100%) of colorectal carcinoma. It was strongly expressed in 12/50 (24%), moderately expressed in 31/50 (62%), and weakly expressed in 7/50 (14%) case. 
Conclusion
• 
